These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15500435)

  • 21. Tirofiban and emergency coronary surgery.
    Shanmugam G
    Eur J Cardiothorac Surg; 2005 Oct; 28(4):546-50. PubMed ID: 16126403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.
    Tcheng JE
    Am Heart J; 2000 Feb; 139(2 Pt 2):S38-45. PubMed ID: 10650315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A defined peptide that inhibits the formation of the glycoprotein IIb and IIIa complex.
    Chiang TM; Zhu J
    Thromb Res; 2005; 115(6):503-8. PubMed ID: 15792682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
    Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
    Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
    Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
    Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.
    De Luca G; Marino P
    Am J Emerg Med; 2009 Jul; 27(6):683-90. PubMed ID: 19751625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban].
    Galli M; Vassanelli C
    Ital Heart J Suppl; 2001 Oct; 2(10):1127-9. PubMed ID: 11723619
    [No Abstract]   [Full Text] [Related]  

  • 29. Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety.
    Van Tuyl JS; Newsome AS; Hollis IB
    Ann Pharmacother; 2019 Jul; 53(7):726-737. PubMed ID: 30646761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress in the field of GPIIb/IIIa antagonists.
    Hanson J; de Leval X; David JL; Supuran C; Pirotte B; Dogné JM
    Curr Med Chem Cardiovasc Hematol Agents; 2004 Apr; 2(2):157-67. PubMed ID: 15320798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
    Mehrotra MM; Heath JA; Smyth MS; Pandey A; Rose JW; Seroogy JM; Volkots DL; Nannizzi-Alaimo L; Park GL; Lambing JL; Hollenbach SJ; Scarborough RM
    J Med Chem; 2004 Apr; 47(8):2037-61. PubMed ID: 15056002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Practical issues of platelet glycoprotein IIb/IIIa receptor inhibition: saving lives and saving money.
    Dippel EJ
    Rev Cardiovasc Med; 2002; 3 Suppl 1():S28-34. PubMed ID: 12439434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of GPIIb/IIIa inhibition with eptifibatide or tirofiban on the expression of cellular adhesion molecules on monocytes.
    Swoboda S; Walter T; Lang S; Wendel HP; Beyer ME; Griesel E; Hoffmeister HM; Gruettner J
    In Vivo; 2014; 28(5):691-7. PubMed ID: 25189879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects.
    Holmes MB; Sobel BE; Schneider DJ
    Am J Cardiol; 1999 Jul; 84(2):203-7. PubMed ID: 10426341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specific glycoprotein IIb/IIIa antagonists and inflammation.
    Ercan E
    Int J Cardiol; 2004 Mar; 94(1):121-2. PubMed ID: 14996486
    [No Abstract]   [Full Text] [Related]  

  • 36. Utility of PFA-100 closure time vs. optical aggregometry in assessing the efficacy of platelet membrane glycoprotein IIb/IIIa antagonists in vitro.
    Stegnar M; Bozic M; Dolenc MS; Anderluh PS; Kikelj D
    Clin Chem Lab Med; 2007; 45(11):1542-8. PubMed ID: 17970708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet glycoprotein IIb/IIIa antagonists: perioperative implications.
    Sreeram GM; Sharma AD; Slaughter TF
    J Cardiothorac Vasc Anesth; 2001 Apr; 15(2):237-40. PubMed ID: 11312488
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacokinetic and pharmacodynamic analysis of TS-943, a selective non-peptide platelet glycoprotein-IIb/IIIa (GPIIb/IIIa) receptor antagonist, using a nonlinear mixed effect model in dogs.
    Furuya A; Nozawa M; Gotoh J; Jingu S; Akimoto M; Higuchi S; Suwa T; Ogata H
    J Pharm Pharmacol; 2002 Jul; 54(7):921-7. PubMed ID: 12162710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists.
    Robinson M; Ginnelly L; Sculpher M; Jones L; Riemsma ; Palmer S; Philips Z; Glanville J
    Health Technol Assess; 2002; 6(25):1-160. PubMed ID: 12583818
    [No Abstract]   [Full Text] [Related]  

  • 40. IIb/IIIa or not IIb/IIIa? That is the question.
    Redwood S
    Int J Clin Pract; 1999 Dec; 53(8):577. PubMed ID: 10692749
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.